CSL's Shortcut from Down Under
This article was originally published in RPM Report
Executive Summary
CSL Ltd. is moving its flu vaccine from Australia (Fluvax) through the US regulatory process in the hopes of importing its product for the 2007 season. CSL is getting help on the US development from the National Institutes of Allergy and Infectious Diseases. The Australian firm may match Glaxo's fast approval for Fluarix in 2005.